Anagliptin twice-daily regimen improves glycemic variability in subjects with type 2 diabetes: Double-Blind, Randomized Controlled Trial.
Eun Young LeeDoo-Man KimJae Myung YuKyung Mook ChoiSin Gon KimKang Seo ParkHyun-Shik SonChoon Hee ChungKyu Jeung AhnSoon Hee LeeKi-Ho SongSu Kyoung KwonHyeong Kyu ParkKyu Chang WonHak Chul Jangnull nullPublished in: Diabetes, obesity & metabolism (2022)
The anagliptin BID regimen for the treatment of type 2 diabetes was superior in blood glucose control after dinner to improve glycemic variability, as indicated by MAGE and TIR but equivalent to the QD regimen in terms of HbA1c and FPG. This article is protected by copyright. All rights reserved.